ACVRL1 and breast carcinoma: Motivated by the previous results indicating an ALK1-dependent specification of a protumorigenic immune state, we yet again exploited our resection-based adjuvant therapy pipeline, this time using the syngeneic 4T1 mammary carcinoma cell line.